Benicar Lawsuit 2026: the $300M Settlement, Sprue-Like Enteropathy & Who Can Still File

Benicar (olmesartan) lawsuits claimed the blood-pressure drug caused sprue-like enteropathy — severe chronic diarrhea and dramatic weight loss resembling celiac disease. In August 2017, Daiichi Sankyo agreed to a settlement program with a fund capped at $300 million covering almost 2,300 pending cases. That program is closed, but individual claims can still be filed in 2026.

  • On August 1, 2017, Daiichi Sankyo announced a settlement program with a fund capped at $300 million, covering olmesartan products Benicar, Benicar HCT, Azor, and Tribenzor; the company admitted no liability.
  • Federal cases were consolidated in Multidistrict Litigation (MDL 2606) in the U.S. District Court for the District of New Jersey, with almost 2,300 filed cases eligible for the settlement.
  • A 2012 Mayo Clinic study described 22 patients who developed sprue-like enteropathy while taking olmesartan, published in the Mayo Clinic Proceedings.
  • In July 2013, the FDA ordered Benicar's label changed to warn of sprue-like enteropathy, noting symptoms could appear months to years after starting the drug.
  • Fifteen bellwether trials were scheduled for fall 2017; Daiichi Sankyo began settling the selected cases before any went to trial.

What sprue-like enteropathy is — and why Benicar cases were different

Sprue-like enteropathy is a severe intestinal condition marked by chronic diarrhea, substantial weight loss, abdominal pain, nausea, and malnutrition that mimics celiac disease. In a person with celiac disease, gluten triggers the damage; in sprue-like enteropathy linked to olmesartan, the blood-pressure drug itself was the suspected trigger. What made these cases distinctive was the pattern: patients tested negative for celiac disease, failed to improve on a gluten-free diet, and then improved after stopping Benicar. Olmesartan is an angiotensin II receptor blocker (ARB) — a common class of blood-pressure medication — and Benicar had been on the market since 2002 before the gastrointestinal signal emerged.

The 2012 Mayo Clinic study that started it all

The litigation's scientific foundation came from Mayo Clinic researchers led by Dr. Joseph Murray. Their 2012 paper in the Mayo Clinic Proceedings described 22 patients who developed sprue-like enteropathy while taking olmesartan. Most had been on the drug for months or years before symptoms appeared, and several had been misdiagnosed with celiac disease for years. When olmesartan was stopped, symptoms resolved; when it was restarted in a few patients, symptoms returned. The researchers proposed that the drug might trigger a cell-mediated immune response in the gut of susceptible patients. The study was small, but the pattern was striking enough that regulators took notice — and patient reports began to accumulate.

The FDA's 2013 label change: the regulatory backbone of every claim

In July 2013, the U.S. Food and Drug Administration (FDA) — the federal agency that approves drugs and their labels — issued a Drug Safety Communication about olmesartan. It announced that labels for Benicar, Benicar HCT, Azor, and Tribenzor would be changed to include sprue-like enteropathy, describing severe chronic diarrhea with substantial weight loss. The FDA noted that symptoms could develop months to years after starting the drug and sometimes required hospitalization. The first lawsuits were filed beginning in January 2014, shortly after the label change, and they were eventually consolidated into MDL 2606 before a New Jersey federal court. The label change matters because it established a documented, dated warning point: claims of inadequate warning hinge on what the manufacturer knew and disclosed, and when.

The $300 million settlement: how the program worked

Daiichi Sankyo's August 1, 2017 announcement set up a settlement program, not a class action. A settlement program is a private agreement in which eligible claimants opt in individually and receive payments from a capped fund after a claims administrator reviews their documentation. The fund was capped at $300 million, and the program required at least 95 percent of eligible litigants and claimants to opt in before it would take effect. Eligible claimants included those with almost 2,300 already-filed cases plus certain unfiled claims. Payouts were to be based on the severity of the injury, the duration of drug use, and the extent of medical treatment — such as hospitalization. A portion of the fund was also reserved for plaintiffs' counsel fees and the claims administrator's costs. Daiichi Sankyo stated the claims were without merit and admitted no liability — a standard term that does not erase the payment.

Who can still file in 2026

The 2017 settlement program is closed, but that does not end the story. New individual claims can still be filed in state courts. Three categories of people have the strongest path. First, people who took olmesartan products and developed chronic diarrhea, severe weight loss, or intestinal damage but never joined the 2017 program. Second, people whose symptoms appeared more recently — sprue-like enteropathy can develop years into treatment, and some patients only connected the drug to their symptoms long after the settlement. Third, family members filing wrongful-death claims where a relative's documented olmesartan injury contributed to death. The key obstacle is time: every state has a statute of limitations — a deadline for filing — and the clock may run from when a person discovered the injury rather than from when they took the drug. Because those discovery-based deadlines are fact-specific, a lawyer must evaluate them individually.

What proof a claim needs

Benicar claims rest on four documented legs. First, a prescription or pharmacy record showing sustained use of an olmesartan product (Benicar, Benicar HCT, Azor, or Tribenzor). Second, medical records documenting the gastrointestinal injury: chronic diarrhea, weight loss, malnutrition, hospitalizations, or biopsy findings of villous atrophy — the flattening of the intestinal lining seen in sprue-like enteropathy. Third, evidence ruling out celiac disease and other causes, typically negative celiac blood tests or the failure of a gluten-free diet to help. Fourth, a treatment record showing improvement after stopping the drug, or an expert opinion connecting the two. Patients who kept their pharmacy records and hospital discharge summaries hold the strongest position.

How to start, step by step

First, request your pharmacy's dispensing history to confirm and date your olmesartan use. Second, gather medical records of the gastrointestinal injury — the ER visits, the gastroenterologist's notes, the celiac test results, the weight chart. Third, write a short timeline: when you started the drug, when symptoms began, when you stopped it, and what changed. Fourth, consult a product-liability lawyer; these cases are typically evaluated on contingency, meaning no upfront fee and the lawyer is paid only if the case resolves. Related drug-injury mass torts show how these cases work: our report on the losartan and irbesartan NDMA lawsuits explains another blood-pressure-drug litigation, and our coverage of the Invokana amputation litigation shows how a closed MDL still leaves filing paths open. For broader context on how drug mass torts proceed, the Problem Solved channel covers these topics in video form: Problem Solved on YouTube.

This article is general information, not legal or medical advice. Speak with a qualified attorney about your specific situation, and never stop or change a prescription without your doctor's guidance.

Who Benefits From This — and Who Does Not

Benicar claims are still alive as individual state-court cases, but they turn on documented intestinal injury, not on having taken the drug.

Who benefits:

  • People who took Benicar, Benicar HCT, Azor or Tribenzor and developed chronic diarrhea, severe weight loss or intestinal damage but never joined the 2017 program: Individual claims can still be filed in state courts.
  • People whose symptoms appeared more recently: Sprue-like enteropathy can develop months to years into treatment, and some patients only connected the drug to their symptoms long after the settlement.
  • Family members filing wrongful-death claims: Where a relative's documented olmesartan injury contributed to death.

Who benefits little or not at all:

  • People who already resolved their claims through the 2017 program: That program, with its fund capped at $300 million, is closed; the live path is an individual state-court claim.
  • Patients whose tests point to celiac disease: Benicar cases are distinctive because patients tested negative for celiac disease and failed to improve on a gluten-free diet before improving after stopping the drug.
  • People without a gastrointestinal injury: The claim rests on documented intestinal damage, so use of the drug alone is not enough.

Related reading: Losartan & Irbesartan NDMA Lawsuits 2026: the $15.26M Settlement Is Closed — but the Cancer Claims Are Still Alive.

Frequently asked questions

Is the Benicar lawsuit still open in 2026?

The 2017 settlement program is closed, but individual lawsuits can still be filed in state courts. A lawyer can tell you whether your state's statute of limitations still allows a claim.

What is sprue-like enteropathy?

It is a severe intestinal condition — chronic diarrhea, substantial weight loss, abdominal pain, and malnutrition — that resembles celiac disease but is triggered by a drug, in this case olmesartan. Patients typically test negative for celiac disease and do not improve on a gluten-free diet.

How much did Daiichi Sankyo pay in the Benicar settlement?

Daiichi Sankyo's August 2017 settlement program created a fund capped at $300 million, covering almost 2,300 pending cases plus certain unfiled claims, subject to a 95 percent opt-in threshold and review by a claims administrator.

Do I need to have been hospitalized to file a Benicar claim?

No. Hospitalization is not required, though documented injury strengthens a claim. Medical records showing chronic diarrhea, weight loss, negative celiac tests, and improvement after stopping the drug are the core proof.

Can I still take Benicar safely?

Sprue-like enteropathy is rare, and many patients took olmesartan without this complication. Never stop or change a prescription on your own; discuss any concerns with your prescribing doctor first.

Who benefits from a Benicar claim — and who does not?

People benefit most when they took an olmesartan product and developed chronic diarrhea, severe weight loss or intestinal damage without ever joining the 2017 program, including people whose symptoms appeared only recently and families filing wrongful-death claims. People who already resolved claims through the closed 2017 program, patients whose tests point to celiac disease rather than the drug, and people without a documented gastrointestinal injury do not benefit.

Watch on YouTube

Problem Solved on YouTube